Rexahn Pharmaceuticals Inc. (RNN)

6.24
AMEX : Health Technology
Prev Close 6.24
Day Low/High 0.00 / 0.00
52 Wk Low/High 4.75 / 28.56
Avg Volume 1.03M
Exchange AMEX
Shares Outstanding 4.02M
Market Cap 25.11M
EPS -0.40
P/E Ratio N/A
Div & Yield N.A. (N.A)
Rexahn Pharmaceuticals Appoints Mark Carthy To Board Of Directors

Rexahn Pharmaceuticals Appoints Mark Carthy To Board Of Directors

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the appointment of Mark P.

Biotech Sector Performance February 2014: Red Hot But...

Biotech Sector Performance February 2014: Red Hot But...

An epic month of biotech stock performance ends with a significant sell off.

4 Biotech Stocks Under $10 Moving Higher

4 Biotech Stocks Under $10 Moving Higher

When a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks look ready to trade higher from current levels.

Rexahn Pharmaceuticals To Present At The 16th Annual BIO CEO & Investor Conference

Rexahn Pharmaceuticals To Present At The 16th Annual BIO CEO & Investor Conference

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter Suzdak, PhD, the Company’s...

4 Health Care Stocks Under $10 to Watch

4 Health Care Stocks Under $10 to Watch

Keep these under-$10 health care stocks on your radar.

It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013

It's Hard to Believe, but Biotech Stocks Are Starting 2014 Hotter Than 2013

Biotech and drug stocks are up almost 9% to start 2014, trouncing the broader market averages.

Rexahn Announces $20 Million Registered Direct Offering

Rexahn Announces $20 Million Registered Direct Offering

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) today announced it has agreed to sell $20 million of units in a registered direct offering at a price of $1.

Rexahn Initiates Phase IIa Clinical Trial Of Archexin® In Patients With Metastatic Renal Cell Carcinoma

Rexahn Initiates Phase IIa Clinical Trial Of Archexin® In Patients With Metastatic Renal Cell Carcinoma

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase IIa clinical proof-of-concept trial to study the safety and efficacy of Archexin ®...

Why Rexahn Pharmaceuticals (RNN) Is Up Today

Why Rexahn Pharmaceuticals (RNN) Is Up Today

Rexahn Pharmaceuticals (RNN) rises Friday morning after an analyst labeled it a "Buy."

Rexahn Initiates Phase Ib Clinical Trial Of RX-3117 For Treatment Of Solid Tumors

Rexahn Initiates Phase Ib Clinical Trial Of RX-3117 For Treatment Of Solid Tumors

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company, announced today the initiation of a Phase Ib clinical trial to study the safety and efficacy of RX-3117 in cancer patients with...

Rexahn Pharmaceuticals To Present At The Biotech Showcase 2014

Rexahn Pharmaceuticals To Present At The Biotech Showcase 2014

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter Suzdak, PhD, the Company’s...

Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin TM (RX-5902)

Rexahn Receives Method Patent For Treatment Of Solid Tumor Cancers For Supinoxin TM (RX-5902)

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced that it has been issued United States Patent, No.

Rexahn Pharmaceuticals To Participate In Brean Capital 2013 Life Sciences Summit

Rexahn Pharmaceuticals To Participate In Brean Capital 2013 Life Sciences Summit

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter D.

Rexahn Pharmaceuticals Reports Third Quarter Financial Results And Pipeline Update

Rexahn Pharmaceuticals Reports Third Quarter Financial Results And Pipeline Update

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer is providing a quarterly update today on its three clinical...

Rexahn Announces $5.3 Million At Market Registered Direct Offering

Rexahn Announces $5.3 Million At Market Registered Direct Offering

Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) today announced it has received commitments from certain institutional investors to purchase an aggregate of $5.

Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform From Ohio State University

Rexahn Pharmaceuticals In-Licenses Novel Oligonucleotide Targeted Drug Delivery Platform From Ohio State University

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the Ohio State Innovation Foundation, an affiliate of The...

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These stocks look ready to trade higher from current levels.

Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For Novel Anti-Cancer Compound RX-3117

Rexahn Pharmaceuticals Announces Publication Of Preclinical Data For Novel Anti-Cancer Compound RX-3117

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced the on-line publication of preclinical results for RX-3117...

Rexahn Awarded Patent In Europe For Cancer Drug Archexin®

Rexahn Awarded Patent In Europe For Cancer Drug Archexin®

Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that the European Patent Office has granted the...

Rexahn Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference On September 9, 2013

Rexahn Pharmaceuticals To Present At The 15th Annual Rodman & Renshaw Global Investment Conference On September 9, 2013

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, today announced that Peter Suzdak, PhD, the Company’s...

Rexahn Pharmaceuticals Provides A Clinical Development And Financial Update

Rexahn Pharmaceuticals Provides A Clinical Development And Financial Update

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of cancer, is providing an update today on its three clinical development...

Rexahn Pharmaceuticals Announces Teva Will Not Exercise Its Option To License RX-3117

Rexahn Pharmaceuticals Announces Teva Will Not Exercise Its Option To License RX-3117

Rexahn Pharmaceuticals (NYSE MKT: RNN) announced today that Teva Pharmaceutical Industries has decided, for strategic reasons, not to exercise its option to license RX-3117 from Rexahn.

Rexahn Pharmaceuticals Initiates Dosing In Phase I Trial Of SupinoxinTM (RX-5902) A Candidate For Treating Solid Cancer Tumors

Rexahn Pharmaceuticals Initiates Dosing In Phase I Trial Of SupinoxinTM (RX-5902) A Candidate For Treating Solid Cancer Tumors

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) a clinical stage biopharmaceutical company announced today the commencement of patient dosing with Supinoxin TM (RX-5902) in a Phase I clinical trial designed to study...

Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering

Rexahn Pharmaceuticals Announces $5.7 Million Registered Direct Offering

Rexahn Pharmaceuticals, Inc. (the “Company”) (NYSE MKT: RNN) today announced that it has received commitments from a single healthcare dedicated institutional investor to purchase an aggregate of ...

Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform

Rexahn Pharmaceuticals In-Licenses Breakthrough Oncology Drug Delivery Platform

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company, announced today that it has signed an exclusive license agreement with the University of Maryland, Baltimore (UMB) for a novel...

Rexahn Pharmaceuticals Announce IND Submission For RX-3117

Rexahn Pharmaceuticals Announce IND Submission For RX-3117

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN) announced today that Teva Pharmaceutical Industries has submitted an Investigational New Drug (IND) application to the US Food and Drug Administration (FDA) for RX-3117, a...

Rexahn Pharmaceuticals Awarded Patent In Japan For Novel Anti-cancer Isoquinolinamine Compounds  

Rexahn Pharmaceuticals Awarded Patent In Japan For Novel Anti-cancer Isoquinolinamine Compounds  

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced that the Japan Patent Office has granted Patent No.

Rexahn Awarded U.S. Patent For Novel Anti-Cancer Compounds

Rexahn Awarded U.S. Patent For Novel Anti-Cancer Compounds

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company developing potential best-in-class oncology therapies, today announced that it has significantly expanded its intellectual...

Rexahn Pharmaceuticals To Present At The 25th Annual ROTH Conference

Rexahn Pharmaceuticals To Present At The 25th Annual ROTH Conference

Rexahn Pharmaceuticals, Inc. (NYSE MKT: RNN), a clinical stage biopharmaceutical company focused on developing first in class therapies for the treatment of cancer, announced today that its new Chief Executive Officer...